Skip to main content
. 2017 May 3;96(5):1155–1159. doi: 10.4269/ajtmh.16-0435

Table 2.

Clinical and therapeutic outcome data from CL patients treated with the combination of pentoxifylline and Sbv or placebo and Sbv

Characteristics Sbv + placebo Sbv + pentoxifylline P value*
Cure rate at 60 days (%) 35/82 (43) 39/82 (47.5) 0.70
Cure rate at 180 days (%) 35/82 (43) 37/82 (45) 0.64
Healing time (days) (M ± SD) 99.7 ± 66.2 98.1 ± 72.7 0.87

CL = cutaneous leishmaniasis; M = media; Sbv = pentavalent antimony; SD = standard deviation.

*

Student's t test.